The approval of Yeztugo, a twice-yearly injectable medication for HIV prevention, has generated a mix of excitement and concern among health experts. While the innovation is seen as a major advancement in the global fight against HIV, its cost is raising alarms about equitable access, particularly for low-income countries. The United States Food and Drug Administration (FDA) recently gave the green light Lenacapavir, the drug margeted as Yeztugo, which is designed to prevent HIV infection when administered every six months. It has been found highly effective in reducing new infections, offering a simpler alternative to daily oral PrEP pills like Truvada and Descovy, or bimonthly options like Apretude.